- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced (unresectable or metastatic) human leukocyte antigen (HLA)-A*02:01-positive uveal melanoma
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 September 2023 PBAC Meetings - (PDF 1.1MB)
- Public Summary Document (PSD) March 2023 September 2023 PBAC Meetings - (Word 356KB)
Related Public Summary Documents
